Affordable Access

deepdyve-link
Publisher Website

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.

Authors
  • Nishiguchi, Shuhei1
  • Urano, Yasuhisa2
  • Suzaki, Keiko2
  • Taniguchi, Atsushi2
  • Scherer, Joseph3
  • Berger, Kristi L3
  • Quinson, Anne-Marie3
  • Stern, Jerry O3
  • Omata, Masao4
  • 1 Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • 2 Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
  • 3 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Connecticut, USA.
  • 4 Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Type
Published Article
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
Publication Date
March 2017
Volume
47
Issue
3
Identifiers
DOI: 10.1111/hepr.12741
PMID: 27153246
Source
Medline
Keywords
License
Unknown

Abstract

In treatment-naïve Japanese patients, faldaprevir 120 mg q.d. plus PegIFNα-2b/RBV was better tolerated than faldaprevir 240 mg q.d. plus PegIFNα-2b/RBV, with at least comparable efficacy. In treatment-experienced patients, most prior relapsers achieved SVR12 with 24 weeks of faldaprevir 240 mg q.d. plus PegIFNα-2b/RBV. Clinicaltrials.gov NCT01579474.

Report this publication

Statistics

Seen <100 times